HCI-047 breast cancer PDX

HCI-047 PDX – Sample taken in 2017 from malignant ascites collected from Caucasian female, age 82 at time of collection with a primary diagnosis of IDC.

Contributors

Inventor Institute
Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose The University of Utah Research Foundation
Cat. #: 162114
Cancer types: Breast cancer
Cancer Subtype: Infiltrating Ductal Carcinoma
Gender: Female
Biopsy Site: Ascites
Patient ethnicity: Caucasian
Treatment History: Pretreated: Patient had undergone radiation therapy to the breast 2005, 2010 and had received systemic treatment of Anastrozole 2010-2102; zoledronic acid 2010-?; exemestane 2012-2013; tamoxifen 2013; letrozole 2013-2014; tamoxifen 2014-2015; fulvestrant 2015; megestrol 2015-2016; capecitabine 2016; taxol 2016; trastuzumab 2016; ado-trastuzumab, emtansine 2016-2017; trastuzumab, taxol 2017; lapatinib, capecitabine 2017 prior to sample collection
Primary citation: Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336
Product description: Human breast cancer patient-derived xenograft (PDX) model that retains high fidelity to original tumour, including spatial structure, intratumour heterogeneity, genomic features, tumour growth rate, metastatic patterns, and drug responses. These highly translatable PDX models can be used to more accurately assess therapeutic efficacy and predict patient responses in preclinical drug validation studies than traditional models. This panel of PDX models includes some of the deadliest forms of breast cancer such as drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and human epidermal growth factor receptor positive (HER2+) tumours. Sample taken in 2017 from malignant ascites collected from Caucasian female, age 82 at time of collection with a primary diagnosis of IDC;2005. Patient had no previous history of smoking. Metastasis was detected in the lymph node, liver, bone, peritoneum, and pleura. Patient had undergone radiation therapy to the breast 2005, 2010 and had received systemic treatment of Anastrozole 2010-2102; zoledronic acid 2010-?; exemestane 2012-2013; tamoxifen 2013; letrozole 2013-2014; tamoxifen 2014-2015; fulvestrant 2015; megestrol 2015-2016; capecitabine 2016; taxol 2016; trastuzumab 2016; ado-trastuzumab emtansine 2016-2017; trastuzumab, taxol 2017; lapatinib, capecitabine 2017 prior to sample collection. Patient characteristics were as follows – ER status: positive (98%), PR status: positive (80%), HER2 status: negative. PDX characteristics were as follows – ER status: negative, PR status: negative, HER2 status: negative. PDX information: PAM50 subtype tests not done and tests to detect metastasis not done.
Initial handling information: Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NRG. NRG(fresh) time to growth: 4 months to 2 cm
Additional notes: Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9
Mice Passaged: Yes
Engraftment Site: Cleared mammary fat pad
Sample Type: Frozen Donor Specimen
Host Strain: Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799
Production details: Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation.
References:

Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946

Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637

Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007

Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602

Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134

Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336

Related Tools for PDX models

Cat. # Tool Name
151147 Anti-p53 [Pab DO-1] Key Info View Tool
162072 HCI-004 breast cancer PDX Key Info View Tool
162074 HCI-006 breast cancer PDX View Tool
162076 HCI-008 breast cancer PDX Key Info View Tool
162077 HCI-009 breast cancer PDX Key Info View Tool

Related News

Representative example of haematoxylin and eosin staining of CRUK0935 T1-R5 TRACERx lung cancer PDX model at early P0 passage.
PDX Models

New non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models now available at CancerTools.org

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.